Peer-reviewed veterinary case report
Complications and outcomes after insulinoma surgery in 48 dogs
By Del Busto, Isaac et al.·Published in Journal of veterinary internal medicine·2020·Institute of Veterinary Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Incidence of postoperative complications and outcome of 48 dogs undergoing surgical management of insulinoma.
- Species:
- dog
Plain-English summary
A group of 48 dogs diagnosed with insulinoma (a type of pancreatic tumor) underwent surgery to remove the tumor. After surgery, the average survival time was about a year, but dogs with early-stage disease lived significantly longer than those with more advanced stages. About one-third of the dogs experienced high blood sugar after surgery, and nearly 20% developed diabetes that persisted. Unfortunately, there were no clear signs to predict which dogs would develop diabetes after their surgery. Overall, while many dogs survived for a good amount of time post-surgery, some faced complications that affected their recovery.
People also search for: dog insulinoma surgery outcome · insulinoma in dogs treatment · dog diabetes after surgery
Abstract
BACKGROUND: Information regarding outcome of dogs undergoing surgical management for insulinoma is based on studies of a small number of dogs. OBJECTIVES: To report the outcomes of dogs undergoing surgery as treatment for insulinoma, the prevalence of postoperative diabetes mellitus (DM) in this group and to determine if development of DM can be predicted. ANIMALS: Forty-eight client-owned dogs, with a histopathological diagnosis of insulinoma, from three European referral hospitals. METHODS: Retrospective observational study. Dogs were identified from a search of electronic hospital records. Cox's regression was used to determine factors associated with postoperative survival and relapse, and logistic regression was used to determine factors associated with the development of DM. RESULTS: Median survival time (MST) was 372 days (range 1-1680 days), with dogs with stage I disease having the longest survival time. Stage I dogs had MST of 652 days (range 2-1680 days), whereas dogs with either stage II or III disease had MST of 320 days (range 1-1260 days; P = 0.045). Postoperative hyperglycemia was identified in 33% (16/48) of the dogs, of which 9 (19% of the total population) developed persistent DM. No factors that could be used as predictors for development of DM were identified. CONCLUSIONS AND CLINICAL IMPORTANCE: Stage of disease and postoperative hypoglycemia were associated with greater odds of relapse and decreased survival time; these could be used when discussing prognosis. In this study, postoperative DM developed more commonly than previously reported, but no factors were identified that might be useful predictors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32212400/